Taysha Gene Therapies, Inc. (TSHA) NASDAQ

1.73

+0(+0.00%)

Updated at December 31 04:00PM

Currency In USD

Taysha Gene Therapies, Inc.

Address

3000 Pegasus Park Drive

Dallas, TX 75247

United States of America

Phone

214 612 0000

Sector

Healthcare

Industry

Biotechnology

Employees

52

First IPO Date

September 24, 2020

Key Executives

NameTitlePayYear Born
Mr. Sean P. NolanChief Executive Officer & Chairman925,3311968
Mr. Kamran Alam CPA, M.B.A.Chief Financial Officer & Corporate Secretary573,3621978
Dr. Sukumar Nagendran M.D.President, Head of Research & Development and Director820,5941967
Hayleigh CollinsDirector of Corporate Communications & Investor Relations0N/A
Ms. Emily McGinnis M.P.H.Chief Patient & External Affairs Officer and Endpoint & Outcome Development Lead0N/A
Mr. Sean McAuliffeChief Business Officer0N/A
Ms. Tracy M. Porter SPHRChief People Officer0N/A
Mr. Frederick Porter Ph.D.Chief of Staff & Technical Operations Officer0N/A
Dr. Steven Gray Ph.D.Chief Scientific Advisor of UT Southwestern Gene Therapy Program0N/A
Berge Minassian M.D.Chief Medical Advisor of UT Southwestern Gene Therapy Program0N/A

Description

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.